基本信息
views: 105
Career Trajectory
Bio
主要从事党政管理和生物化学与分子生物学科研和教学工作。在血管平滑肌细胞表型调制、增殖与分化及其信号转导等方面,进行了一系列较为深入系统的研究。作为项目负责人已完成国家自然科学基金资助课题8项,“973”项目子课题 1项,卫生部、教育部和人事部资助课题5项,河北省自然科学基金和科技攻关项目10余项;在国内外学术刊物上发表论文200多篇,其中,在Circ Res、 Cell Res、Hypertension等国际著名学术期刊上发表SCI论文70余篇;主编国家级规划教材《生物化学》及其他学术著作4部;获国家教育部、卫生部科技进步三等奖各1项,河北省科技进步一等奖4项,河北省教学成果一等奖1项,获国家发明专利1项;9名博士毕业生获河北省优秀博士学位论文;两次受邀在美国KLF专题研讨会上做报告,多次在国内相关学术会议上报告;受邀为多家SCI杂志评审血管平滑肌细胞表型调制方面的论文。国家级有突出贡献的中青年专家,全国杰出专业技术人才,全国留学回国人员先进个人,省管优秀专家,河北省高端人才,享受国务院特殊津贴专家。
Research Interests
Papers共 354 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Bin Zheng,Wei-Na Yin,Toru Suzuki, Xin-Hua Zhang,Yu Zhang,Li-Li Song, Li-Shuang Jin,Hong Zhan,Hong Zhang,Jin-Shui Li,Jin-Kun Wen
Molecular therapy : the journal of the American Society of Gene Therapyno. 3 (2024): 855-855
CELL RESEARCH (2024)
Zheng Lei, Zhang Qianfan,Lian Hongguang,Wang Wenli, Li Liangsheng, Zhen Zekun, Li Ziyan, Zhao Lingdan, Zhang Tingting,Zheng Bin,Wang Chao,Zhang Wei,
Nanotechnology Reviewsno. 1 (2024): C7-12
Bin Zheng,Wei-na Yin, Toru Suzuki,Xin-hua Zhang,Yu Zhang, Li-li Song, Li-shuang Jin, Hong Zhan,Hong Zhang, Jin-shui Li,Jin-kun Wen
MOLECULAR THERAPYno. 3 (2024): 855-855
Cell Researchno. 4 (2024): 1-1
Yu Zhang,Bo-yang Zheng, Qian-fan Zhang, Ya-nan Zhao, Qi-ming Yu,Xin Liu, Si-ying Ding, Shuang-shuang Qian, Han Wu, Qian-yu Wu,Yu-han Zhang, Lei Zheng,
Biomaterials (2024): 122613-122613
Yu Zhang, Bo Zheng, Qian-fan Zhang,Yanan Zhao,Xin Liu, Shou-Nian Ding, S. Qian, Yu Qian, Wei Han, Qihui Wu,Yuhan Zhang,Zheng Li,
Research Square (Research Square) (2023)
Cell Death & Differentiationno. 12 (2023): 1-15
crossref(2023)
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn